Swiss National Bank acquired a new position in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,700 shares of the company’s stock, valued at approximately $426,000.
A number of other institutional investors have also recently added to or reduced their stakes in EIDX. BNP Paribas Arbitrage SA bought a new position in Eidos Therapeutics during the 1st quarter worth approximately $80,000. SG Americas Securities LLC bought a new position in Eidos Therapeutics during the 2nd quarter worth approximately $125,000. Metropolitan Life Insurance Co NY bought a new position in Eidos Therapeutics during the 1st quarter worth approximately $143,000. MetLife Investment Advisors LLC bought a new position in Eidos Therapeutics during the 1st quarter worth approximately $198,000. Finally, Fiduciary Trust Co. bought a new position in Eidos Therapeutics during the 1st quarter worth approximately $211,000. 32.46% of the stock is currently owned by institutional investors and hedge funds.
In other news, major shareholder Bridgebio Pharma, Inc. bought 882,353 shares of the firm’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was acquired at an average cost of $29.90 per share, with a total value of $26,382,354.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Uma Sinha sold 5,000 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $36.13, for a total transaction of $180,650.00. The disclosure for this sale can be found here. Insiders sold 30,000 shares of company stock worth $1,171,700 over the last quarter. 70.10% of the stock is owned by corporate insiders.
Eidos Therapeutics (NASDAQ:EIDX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.01). Equities research analysts anticipate that Eidos Therapeutics Inc will post -1.7 earnings per share for the current fiscal year.
EIDX has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Eidos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 23rd. BTIG Research raised their target price on shares of Eidos Therapeutics to $56.00 and gave the stock a “buy” rating in a report on Friday. BMO Capital Markets raised their target price on shares of Eidos Therapeutics to $50.00 and gave the stock an “outperform” rating in a report on Monday, July 22nd. Finally, Piper Jaffray Companies started coverage on shares of Eidos Therapeutics in a report on Monday, July 22nd. They set an “overweight” rating and a $55.00 target price on the stock. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $37.57.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Story: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding EIDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eidos Therapeutics Inc (NASDAQ:EIDX).
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.